Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Weighs greater than or equal to (\>=) 45 kilogram (kg) and has a body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2), inclusive at Screening.~Exclusion Criteria:~1. Has received TAK-831 in a previous clinical study.~2. Has poor peripheral venous access.~3. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days prior to first dose of study drug.~4. Has any dietary restrictions or preferences that may interfere with the conduct of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- TAK-831 400 mg Fasted + TAK-831 400 mg Fed (Type: EXPERIMENTAL): TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
- TAK-831 400 mg Fed + TAK-831 400 mg Fasted (Type: EXPERIMENTAL): TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).